• Home
• Partneringtools
• Reports

• In-licensing
• Out-licensing
• Companies

• Articles
• Events
• Outsourcing

• Consulting
• Jobs
• Forums

• About us
• Products
• Newsletter

Pharmalicensing Ltd
is a division of

— HONG KONG, April 22

HONG KONG, April 22 /PRNewswire/ -- OrbusNeich's Genous Bio-engineered R stent will be featured at a sponsored symposium during Angioplasty Summit TCT 2008 Asia Pacific.

The symposium, which will take place on April 23 at the Convention Center of Sheraton Grande Walkerhill Seoul Hotel in Seoul, Korea, includes:

-- "Opening Address" by Seung-Jung Park, the symposium's chairperson, from 12:30 p.m.-12:35 p.m. -- "Endothelial Progenitor Cell Capture Technology and Beyond" by Michael Kutryk from 12:35 p.m.-12:50 p.m. -- "TRIAS HR Pilot Study Long Term Follow-up" by Robbert de Winter of the Academic Medical Center, Amsterdam, from 12:50 p.m.-1:05 p.m. -- "HEALING AMI" by Harry Suryapranata from 1:05 p.m.-1:20 p.m. -- "Q&A Followed by Closing Remarks" by Seung-Jung Park from 1:20 p.m.-1:30 p.m.

"Recent data has highlighted the need for a safer alternative to drug-eluting stents," said Seung-Jung Park. "The data we have seen from both the TRIAS HR Pilot study and the registries underline Genous' superior safety profile with regards to late stage thrombosis."

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous Bio-engineered R stent, an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com .

Web site: http://www.OrbusNeich.com

Industry news: Pharmalicensing provides comprehensive industry coverage.

Products:	Partnering Consulting	Partnering Search	Company Profiling	Comparision	Partneringtools	Reports
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Outsourcing
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search	Add your event
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic	Post your article
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Company releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us